{
  "model": "gemini-3.1-pro-preview",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "All required data has been drafted and written successfully.\n\n**Checklist of written output files:**\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
    "thoughts": "**Reviewing File Generation**\n\nI've successfully written all four files, ensuring the generated JSON content adheres to the specified schemas. I've also verified that the constraints are met, including line references, quoted strings, and relative paths. Now, I'm reviewing the study overview and preparing the checklist for completion.\n\n\n**Validating File Outputs**\n\nI've confirmed the four JSON output files are generated correctly, matching all specified schemas. Every constraint has been carefully checked and validated. Now, I'm focusing on the final checklist before signaling completion of the process. I am ready to submit the list of files as a closing step.",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gemini-3.1-pro-preview",
        "thoughts": "**Initiating Extraction and Summary**\n\nI've just begun parsing the provided instructions in `TASK.md`. I'm focusing on understanding the goal â€“ to extract and summarize files, adhering to the report and schemas provided. The two-phase draft-and-write process is also clear. I'm aware of the need to avoid getting stuck in rewrite loops.\n\n\n**Reading and Interpreting TASK.md**\n\nI've successfully read `TASK.md` and have identified the main components. My current focus is on the two-phase approach (draft then write), and I'm beginning to identify the schemas and reporting requirements. I am actively attempting to determine how those are defined and structured in the provided markdown file.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md"
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools."
          }
        ],
        "usage": {
          "promptTokens": 240,
          "responseTokens": 13,
          "thinkingTokens": 124,
          "totalTokens": 377
        },
        "costUsd": 0.002124
      },
      {
        "step": 2,
        "modelVersion": "gemini-3.1-pro-preview",
        "thoughts": "**Generating JSON Outputs**\n\nI'm currently focused on the JSON file generation task. I've begun structuring the `study_overview.json` file, using the provided schema as a guide. Next up, I'll tackle the `quantitative_findings.json` file.\n\n\n**Outlining JSON Creation**\n\nI'm now shifting my focus to constructing all four JSON files. I've noted the required output files and their corresponding schemas. My immediate next steps are to ingest both the `input/report.md` file and all four schema files to begin the JSON generation.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md"
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified."
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }"
          }
        ],
        "usage": {
          "promptTokens": 736,
          "responseTokens": 91,
          "thinkingTokens": 142,
          "totalTokens": 969
        },
        "costUsd": 0.004268
      },
      {
        "step": 3,
        "modelVersion": "gemini-3.1-pro-preview",
        "thoughts": "**Analyzing Paper Schemas**\n\nI'm focused on the structure of the JSON objects. Right now, I'm defining the `output/study_overview.json`. The schema demands a `paper` object containing fields like `title`, which must be a string and is validated to be at least 10 characters long. I've noted the title for the paper.\n\n\n**Enumerating Object Fields**\n\nI'm presently building the `output/study_overview.json` schema, focusing on its `paper` object. I have established that the paper's title requires validation. Now, I'm working through the `doi` and `publication_year` fields, making sure their types and constraints are correctly assigned and validated. I'm noting the need for enum validation on fields like `domain` and `study_type`.\n\n\n**Implementing JSON Schemas**\n\nI'm deep in the process of defining the `output/study_overview.json` schema. I've now integrated the `core_question`, and am currently detailing the structure for `datasets_or_cohorts`, which will involve an array of objects. I'm also preparing to incorporate the constraints around `major_limitations`, ensuring it adheres to the length requirements. Next, I'll turn my focus to  `output/quantitative_findings.json` .\n\n\n**Outlining JSON Specifications**\n\nI am now progressing through the schema details for `output/study_overview.json`. I've structured the `datasets_or_cohorts` array, and am incorporating the `major_limitations` constraints. Moving on to `output/quantitative_findings.json`, I'll define its `findings` and `controls_or_null_results` objects.\n\n\n**Synthesizing JSON Components**\n\nI am currently working on the complete schema definitions, beginning with `output/study_overview.json` and moving on to `output/quantitative_findings.json`. I have begun drafting the array of `findings`, defining the data types for each field. Now I'll start defining claims in  `output/claim_audit.json` to complete the required JSON specifications.\n\n\n**Finalizing Schema Structures**\n\nI'm presently building the `output/claim_audit.json` schema, focusing on its `claims` object. I have now established the format of each `claim`, including its strength, its evidence and caveats. I am also working on `evidence` which include `quote` and the `line_ref`. I am in the final stages, defining the necessary constraints for completing the data structures.\n\n\n**Structuring Core Objects**\n\nI am now focusing on drafting each JSON object, starting with `output/study_overview.json` and defining the detailed specifications for `paper`, including `title`, `doi`, `publication_year`, `domain`, and `study_type`. I've also focused on the core question, and datasets or cohorts. I've noted the `major_limitations`, as well.\n\n\n**Structuring Claim Evidence**\n\nI'm now detailing `output/claim_audit.json`. I've outlined the core claims and their strengths, and am now working to build out the `evidence` arrays. I've begun to fill the `quote` and `line_ref` fields, ensuring I have the precise text from the provided report lines. I'm focusing on consistency in formatting as I define each citation.\n\n\n**Defining Public Summary**\n\nI'm now outlining the structure for the `output/public_summary.json` schema. I'll focus on the fields `headline`, ensuring it adheres to the length constraints. Also, I'm now drafting the `plain_language_summary` to meet the length requirements.\n\n\n**Defining Summary Structures**\n\nI'm now defining the structure for the `output/public_summary.json` schema. I've built the `headline` and I'm drafting the `plain_language_summary`. After that, I will incorporate the `what_is_new` and `why_caution_is_needed` arrays. I'm focusing on ensuring these summaries are clear and concise, with an eye towards length constraints and proper glossary components.\n\n\n**Defining Public Summary Content**\n\nI am now carefully constructing the `output/public_summary.json` schema, including all of its various components and validations. I'm focusing on the `headline` and `plain_language_summary` to meet the length requirements. I'm also preparing to establish `what_is_new` and `why_caution_is_needed` arrays to enhance the clarity of the public overview.\n\n\n**Summarizing Content Structures**\n\nI'm now fully immersed in the creation of the `output/public_summary.json` schema. I've successfully drafted the essential components, including the `headline` and `plain_language_summary`, carefully adhering to the required length constraints. I have also built the array elements and their respective text: `what_is_new` and `why_caution_is_needed`. After this, I'm focusing on validating the information for the `glossary` definitions.\n\n\n**Defining Report Structures**\n\nI'm now building the `output/public_summary.json` schema, including all necessary validation steps. I have built out the `headline` and `plain_language_summary`, ensuring they meet the required length constraints. Furthermore, I have carefully created the array elements, including `what_is_new`, `why_caution_is_needed`, and `glossary` definitions. After reviewing the glossary components, I'm verifying the open questions to complete.\n\n\n**Reviewing Public Content**\n\nI am now meticulously crafting the `output/public_summary.json` schema, paying close attention to all necessary validation steps. I'm focusing on the `headline` and `plain_language_summary` to meet the length requirements. Additionally, I've constructed the array elements, incorporating `what_is_new`, `why_caution_is_needed`, and also all the components for `glossary` definitions. After these items are verified, I'll review all the open questions.\n\n\n**Creating Final Outputs**\n\nI'm now creating the JSON outputs, ensuring each file adheres to its specific schema. I've double-checked all field constraints, including string lengths, and array sizes. The goal is now to run and validate the outputs.\n\n\n**Generating JSON Outputs**\n\nI'm now generating all the JSON output files. I've successfully checked each schema to ensure compliance with all constraints, including string lengths, and array sizes. I'm now proceeding with the final generation and validation.\n\n\n**Finalizing JSON Generation**\n\nI'm now generating the JSON files and completing the JSON outputs. I am ensuring that each file adheres to all the constraints that I have established.\n\n\nI've completed generating the JSON files, following all required constraints. I am now at the phase of validating the outputs against their specified schemas.\n\n\nI've completed all JSON output files, now conforming to the specific schema requirements. I'm satisfied all fields have the proper constraints to ensure validity.\n\n\n**Finalizing File Outputs**\n\nI'm now generating each of the JSON output files. After careful review of all the schemas, I'm confident that all constraints have been satisfied, and all fields are in the correct format. The final step is to validate the generated JSON files against their corresponding schemas.\n\n\nI have written all JSON files and made certain that each object, and all of its fields and values, align with their corresponding schema's requirements.\n\n\n\n**Verifying JSON Files**\n\nI am now validating each of the generated JSON files against their corresponding schemas. After confirming the outputs' adherence to all defined constraints, I'm ready to perform the validation checks.\n\n\n**Producing the Outputs**\n\nI am now writing each JSON file, based on the specifications of the schema. I'm verifying the individual elements, checking string lengths, number of array elements, and data formats for all of the data. The next step is to validate the generated JSON files against their corresponding schemas.\n\n\n**Executing File Generation**\n\nI'm now generating all JSON files, based on the completed schema specifications. I've double-checked all field constraints including the correct data formats and array lengths. I will now validate all outputted files.\n\n\n**Finalizing File Generation**\n\nI'm now generating each of the JSON output files. After careful review of all the schemas, I'm confident that all constraints have been satisfied, and all fields are in the correct format. The final step is to validate the generated JSON files against their corresponding schemas.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments for combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls including vaccine only, ICI only, and vehicle.\"\n    },\n    {\n      \"id\": \"human-retro\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Total number of patients in the retrospective human metastatic cohort.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43\",\n      \"description\": \"Patients in the human retrospective cohort who were vaccinated.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87\",\n      \"description\": \"Patients in the human retrospective cohort who were unvaccinated.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination effectively triggers local type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination broadens the tumor immunopeptidome and MHC-I presentation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination improves subsequent sensitivity to checkpoint blockade therapies.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Human patients with prior mRNA vaccination have improved outcomes under ICI therapy.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"SARS-CoV-2 mRNA Vaccines Show Potential to Make Tumors More Responsive to Immunotherapy\",\n  \"plain_language_summary\": \"Immunotherapy works well for some cancers but fails in others because the tumors are able to hide from the immune system. This study investigated whether injecting an mRNA vaccine directly into tumors could act like a flare, alerting the immune system and creating an inflammatory state. The researchers found that mRNA vaccines triggered an immune reaction, expanding the number of targets displayed on the tumor surface. This made the tumors significantly more susceptible to subsequent immune checkpoint blockade therapies in mouse models. The researchers also observed that among human metastatic cancer patients, those who had received an mRNA vaccination showed better survival rates when treated with immunotherapy, although this finding is preliminary and requires further randomized clinical trials.\",\n  \"what_is_new\": [\n    \"Intratumoral injection of mRNA vaccines can trigger beneficial local type I interferon signaling in tumors.\",\n    \"The mRNA vaccine expands the landscape of tumor antigens presented by MHC-I molecules.\",\n    \"Both mouse models and human retrospective data point to a synergistic effect when combining mRNA vaccines with anti-PD-L1 checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is retrospective and non-randomized, meaning other factors could have influenced patient survival.\",\n    \"The timing of vaccination relative to starting immunotherapy varied among patients, complicating interpretations.\",\n    \"Some mechanistic responses were only seen strongly in specific animal models, rather than universally across all types of cancer.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors\",\n      \"definition\": \"A type of cancer immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete set of protein fragments (peptides) displayed on the surface of cells, which the immune system uses to recognize threats.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Proteins produced by host cells in response to pathogens that help regulate the activity of the immune system.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"Major histocompatibility complex class I molecules, which display protein fragments from inside the cell onto the cell surface for T cells to inspect.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will these findings hold true in large-scale, prospective randomized clinical trials?\",\n    \"Which specific types of tumors are most likely to benefit from this combination therapy approach?\",\n    \"What is the optimal timing and dosing schedule for mRNA vaccination relative to immune checkpoint blockade?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json"
          }
        ],
        "usage": {
          "promptTokens": 5548,
          "responseTokens": 2718,
          "thinkingTokens": 7750,
          "totalTokens": 16016
        },
        "costUsd": 0.136712
      },
      {
        "step": 4,
        "modelVersion": "gemini-3.1-pro-preview",
        "text": "All required data has been drafted and written successfully.\n\n**Checklist of written output files:**\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
        "thoughts": "**Reviewing File Generation**\n\nI've successfully written all four files, ensuring the generated JSON content adheres to the specified schemas. I've also verified that the constraints are met, including line references, quoted strings, and relative paths. Now, I'm reviewing the study overview and preparing the checklist for completion.\n\n\n**Validating File Outputs**\n\nI've confirmed the four JSON output files are generated correctly, matching all specified schemas. Every constraint has been carefully checked and validated. Now, I'm focusing on the final checklist before signaling completion of the process. I am ready to submit the list of files as a closing step.",
        "toolCalls": [],
        "usage": {
          "promptTokens": 8310,
          "responseTokens": 75,
          "thinkingTokens": 119,
          "totalTokens": 8504
        },
        "costUsd": 0.018948
      }
    ],
    "totalCostUsd": 0.162052
  }
}
